UPDATE: Auriga Raises Price Target on the Medicines Company to $25
According to Auriga, the Medicines Company (NASDAQ: MDCO) price target is raised to $25.
Auriga said that MDCO had a strong quarter due to high demand of Angiomax, with results handily beating consensus on both revenue and EPS. “We reiterate BUY and raise price target to $25.00.”
The Medicines Company closed yesterday at $22.28.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.